Novartis Returns OUS Rights for Jetrea to ThromboGenics

September 22, 2017: By Jon Swedien

April 2014 OMP ThromboGenics’ JetreaThromboGenics regained full global rights to Jetrea after reaching an agreement with Novartis, whose subsidiary, Alcon, had held the rights outside the US (OUS), ThromboGenics announced Sept. 18.

Jetrea (ocriplasmin), launched in January 2013, is a one-time, single intravitreal injection to treat adults with symptomatic vitreomacular adhesion.

In 2012, ThromboGenics struck an agreement with Novartis to license Jetrea’s OUS rights to Alcon.

Under that agreement, ThromboGenics received an upfront payment of €75 million ($97.9 million, conversion March 16, 2012) and was eligible to receive up to €300 million ($391.5 million, conversion March 16, 2012) more in potential milestone payments.

Under the new agreement, Novartis will pay ThromboGenics €53.7 million ($64.1 million, conversion Sept. 18, 2017) in cash and make a forthcoming equity investment of €10 million ($11.1 million, conversion Sept. 18, 2017) in ThromboGenics capital, ThromboGenics said.

Following the agreement, ThromboGenics will have more than €120 million in cash, the Belgium firm said.

The agreement stipulates Alcon and Novartis will work closely with ThromboGenics to ensure continuity and access to Jetrea for existing and future customers, ThromboGenics said.

In March 2017, ThromboGenics announced it would take an impairment charge of €26.6 million to align its Jetrea goodwill value with continued lower-than-expected sales.

Novartis took an impairment charge of $119 million on Jetrea in 2015.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022